Lan Zhu serves as the Director at Shanghai Chempartner, where she leverages over 20 years of extensive experience in pharmaceutical research and development, particularly in the realm of metabolic and cardiovascular diseases. Her expertise in biomarker assay development, validation, and implementation is pivotal in advancing...
Lan Zhu serves as the Director at Shanghai Chempartner, where she leverages over 20 years of extensive experience in pharmaceutical research and development, particularly in the realm of metabolic and cardiovascular diseases. Her expertise in biomarker assay development, validation, and implementation is pivotal in advancing drug candidates from the discovery phase through to clinical trials. With a specialized focus on Type II Diabetes drug discovery, Lan has honed her skills in bioanalysis and cell-based assays, utilizing techniques such as ELISA to ensure robust and reliable data generation.
At Shanghai Chempartner, Lan leads key projects that integrate cutting-edge methodologies in in vitro and cell biology, driving innovation in drug discovery processes. Her strategic oversight in project management and outsourcing to Central Research Organizations (CROs) enhances operational efficiency and accelerates timelines for critical research initiatives. Lan's adeptness in molecular biology and assay development allows her to navigate complex challenges in the pharmaceutical landscape, ensuring that her team not only meets but exceeds industry standards.
Her collaborative approach fosters strong partnerships with both internal teams and external stakeholders, facilitating seamless communication and knowledge transfer. As a thought leader in the field, Lan is committed to advancing therapeutic solutions for metabolic diseases, making significant contributions to the scientific community and ultimately improving patient outcomes. Through her leadership at Shanghai Chempartner, she continues to shape the future of drug discovery, driving forward the development of innovative therapies that address pressing health challenges.
